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ABSTRACT
Papillary Thyroid Carcinoma (PTC) is the most frequent thyroid cancer. Although 
several PTC-specific miRNA profiles have been reported, only few upregulated 
miRNAs are broadly recognized, while less consistent data are available about 
downregulated miRNAs. In this study we investigated miRNA deregulation in PTC 
by miRNA microarray, analysis of a public dataset from The Cancer Genome Atlas 
(TCGA), literature review and meta-analysis based on a univocal miRNA identifier 
derived from miRBase v21. A list of 18 miRNAs differentially expressed between PTC 
and normal thyroid was identified and validated in the TCGA dataset. Furthermore, we 
compared our signature with miRNA profiles derived from 15 studies selected from 
literature. Then, to select possibly functionally relevant miRNA, we integrated our 
miRNA signature with those from two in vitro cell models based on the PTC-driving 
oncogene RET/PTC1. Through this strategy, we identified commonly deregulated 
miRNAs, including miR-451a, which emerged also by our meta-analysis as the most 
frequently reported downregulated miRNA. We showed that lower expression of 
miR-451a correlates with aggressive clinical-pathological features of PTC as tall cell 
variant, advanced stage and extrathyroid extension. In addition, we demonstrated 
that ectopic expression of miR-451a impairs proliferation and migration of two PTC-
derived cell lines, reduces the protein levels of its recognized targets MIF, c-MYC and 
AKT1 and attenuates AKT/mTOR pathway activation.
Overall, our study provide both an updated overview of miRNA deregulation in 




Thyroid cancer (TC) is the most frequent malignancy 
of the endocrine system. Papillary thyroid carcinoma 
(PTC) is the prevalent histotype (approximately 80% of 
all TCs) and its incidence has steadily increased over the 
past 40 years [1, 2]. PTCs comprise several histological 
subtypes characterized by different morphology and 
prognosis; among these the classical, follicular and tall 
cell variants are the most common.
Most PTCs are effectively treated by surgical 
removal followed by adjuvant radioactive iodine (RAI) 
therapy and the 5-years survival is over the 95% [3]. 
Nevertheless, a fraction of patients do not respond to RAI 
therapy and/or progress to metastatic disease; in these 
cases the prognosis is poor and the 10-years survival drops 
to 10% [4]. Although several treatments have been tested 
in these patients, limited benefits have been achieved and 
effective therapies are still lacking [5].
Starting from the identification of the first 
oncogene in PTC, RET/PTC1 [6], in almost 30 years 
of investigations several tumor-driving genetic events 
have been identified and characterized. A remarkable 
contribution in this sense has recently been made by the 
work of The Cancer Genome Atlas (TCGA) Research 
Network [7] that, by a multiplatform analysis of almost 
500 PTCs, the largest cohort studied to date, extended and 
advanced the knowledge of the biology and the genomic 
landscape of this tumor. Their discoveries not only 
confirmed the well known drivers as BRAF (60%) and RAS 
(13%) mutations and RET and NTRK gene fusions (8.8%), 
but also identified additional PTC-driving alterations as 
novel gene fusions and mutations in EIF1AX gene as well 
as in gene involved in DNA repair, chromatin remodeling 
and PI3K/AKT pathway. Although TCGA findings led 
to a significant reduction of the fraction of PTCs with 
unknown genetic drivers (from 25% to less than 4%), the 
mechanisms underlying the development and progression 
of PTC remain to be fully elucidated.
Recent evidence indicated that in addition to 
genetic alterations PTC, like the majority of tumors, 
is characterized by aberrant expression of microRNAs 
(miRNAs), a class of small noncoding RNAs that regulate 
gene expression at post-transcriptional level. Since 
miRNAs are able to regulate multiple targets, their role in 
biological processes results simultaneously powerful and 
complex. In the last years many studies have investigated 
miRNA deregulation in PTC [8–21] and their utility as 
diagnostic and prognostic markers has already been 
suggested [22]. Overall in PTC, miRNA upregulation is 
well supported and specific miRNAs have been broadly 
recognized (e.g. miR-146b and miR-221/-222 cluster), 
whereas miRNA downregulation has been reported only 
by a subset of studies and with low consistency [23, 24]. 
Even though several functional studies have addressed 
the role of specific miRNAs in thyroid carcinogenesis 
[22, 24], the involvement of others remains unexplored. 
Further studies are thus required to better understand the 
consequences of miRNA deregulation in PTC as well 
as the molecular processes and networks in which these 
miRNAs operate.
miR-451a is located on chromosome 17q11.2 and its 
biogenesis occurs via a non-canonical pathway that depend 
on Ago2 protein [25]. miR-451a aberrant expression and 
role in tumor pathogenesis and development have already 
been reported in lung, breast, gastric and colorectal cancer, 
as well as in glioma and leukemia (reviewed in [25]), and 
more recently confirmed in many other types of cancers 
[26–32]. Moreover, in several malignancies it was also 
reported a significant association between low miR-451a 
expression and aggressive clinical-pathological features as 
lymph node metastases (LNM) [29, 32], dedifferentiation 
[29, 31], advanced TNM stage [29–31], metastases [26, 
30], recurrence [26] and reduced overall survival [27, 30]. 
Several miR-451a validated targets have been reported 
(http://miRTarBase.mbc.nctu.edu.tw/) [33] including, 
among the others, MIF, c-MYC and AKT1.
In the present study we investigated miRNAs 
deregulation in PTC. We performed miRNA microarray 
analysis in a small proprietary series of PTCs and validated 
the identified miRNA signature in an independent 
and larger dataset publicly available from TCGA [7]. 
Furthermore, we carried out a literature review and meta-
analysis and compared our miRNA signature with those 
derived from 15 published studies. Then, we combined 
our miRNA signature, with those derived from two in 
vitro cell models based on the PTC-driving oncogene 
RET/PTC1 previously established by us [34]. Based on 
this analysis, we identified four consistently deregulated 
miRNAs: miR-222-3p, miR-199a-3p, miR-214-3p and 
miR-451a. Notably, miR-451a emerged also by our meta-
analysis as the most frequently reported downregulated 
miRNA in PTC. Because the involvement of miR-451a 
has not been investigated in PTC so far, we focused on 
miR-451a attempting to explore its role in PTC.
RESULTS
miRNA expression profiles in PTC clinical 
samples
miRNA expression was initially assessed by 
microarray in a series of 19 PTC and 5 normal thyroid 
tissues collected in our Institute (clinical-pathological 
features available in Supplemental Table S1). By class 
comparison analysis, we identified a list of 18 miRNAs 
significantly deregulated (absolute FC≥1.5; FDR<0.05) 
in PTC compared to normal thyroid (Supplemental Table 
S2); these included 9 upregulated miRNAs (miR-146b-
5p, miR-221-3p, miR-222-3p, miR-21-5p, miR-34a-5p, 
miR-181a-5p, miR-15a-5p, miR-221-5p, miR-181b-5p) 
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and 9 downregulated miRNAs (miR-451a, miR-7-5p, 
miR-199b-5p, miR-199a-3p, miR-195-5p, miR-100-5p, 
miR-365a-3p, miR-99a-5p, miR-214-3p). Hierarchical 
clustering analysis based on the identified miRNA 
list (Figure 1A), showed a clear separation between 
PTC and normal thyroid samples, as expected, and a 
partial sub-stratification of PTC samples according to 
histological type. Four major clusters were detected: 
cluster 1 including all normal thyroid samples (5/5; p = 
0.0001); cluster 2 including follicular variant PTCs (3/5; 
p = 0.0049); cluster 3 enriched for classical variant PTCs 
(5/8; p = 0.0069) and cluster 4 enriched for tall cell variant 
PTCs (4/5; p = 0.0474).
As validation set, we took advantage of public data 
available from TCGA [7] and analyzed the expression 
of the 18 miRNAs in 499 PTCs and 59 normal thyroid 
samples. We confirmed the significant deregulation of 
both upregulated and downregulated miRNAs (Figure 
1B–1C) in this independent and larger cohort. As further 
validation, hierarchical clustering analysis of the 59 
matched PTC/adjacent normal thyroid samples included 
in TCGA dataset was performed based on the identified 
miRNAs list (Supplemental Figure S1). Our signature 
efficiently separated tumor samples from their normal 
counterpart also in this series of PTCs.
Meta-analysis of miRNA expression profiles in 
PTC versus normal thyroid
As previous studies have investigated miRNA 
deregulation in PTC, we explored to what extent our 
signature was consistent with literature data. We first 
carried out a systematic literature review and meta-
analysis. To overcome the difficulties and heterogeneity 
associated with multiple datasets, we applied specific 
criteria of selection (see Materials and Methods) and 
focused only on studies reporting miRNA deregulation in 
PTC compared to normal thyroid tissue. Fifteen studies 
were selected from literature (Table 1). To assess the 
degree of concordance among studies, miRNA profiles 
were updated according to the most recent miRBase 
release (Supplemental Datasets and Supplemental Table 
S3; data processing fully described in Supplemental 
Materials and Methods). Overall we observed a common 
pattern of deregulation (Figure 2); in particular we 
confirmed better overlap across the studies for the 
upregulated than downregulated miRNAs, as already 
reported [23, 24]. Regarding upregulated miRNAs, 
along with miR-146b-5p, miR-221-3p and miR-222-
3p, identified as top overexpressed in almost all studies, 
we found a set of miRNAs (miR-34a-5p, miR-181b-5p, 
miR-21-5p and miR-31-5p) consistently reported in at 
least half of the analyzed studies. Interestingly, a more 
in-depth analysis revealed that a number of the identified 
miRNAs belong to gene families (miR-221, miR-146 and 
miR-181) or clusters (miR-221/222 and miR-181a/181b) 
or derive from the same hairpin precursor (Supplemental 
Figure S2A).
Regarding downregulated miRNAs, our meta-
analysis revealed a set of miRNAs commonly reported, 
especially in the most recent studies; these included 
the most frequently identified miR-451a, miR-138-
5p, miR-144-5p and miR-486-5p, and, reported with a 
lower frequency, miR-100-5p, miR-204-5p, miR-195-5p, 
miR-199b-5p, and miR-7-5p. In addition, also among 
downregulated miRNAs we could identify miRNAs 
included either in gene families (miR-7, miR-199 and 
miR-15) or clusters (miR-451a/144 and miR-7-2/1179) 
or derived from the same precursor (Supplemental 
Figure S2B).
When we compared our signature with those derived 
from literature, we observed a consistent overlap (Figure 
2 and Supplemental Figure S2). In addition, our signature 
identified two further relevant miRNAs: miR-214-3p, 
included in the miR-199a-2/214 cluster, and miR-99a-
5p, included along with miR-100-5p, in the miR-10 gene 
family (Supplemental Figure S3).
Combined analysis of miRNAs in PTC clinical 
samples and in vitro cell models
With the aim of selecting from our signature those 
miRNAs that could be functionally relevant and represent 
the best candidate for further analyses, we combined our 
miRNA signature with those derived from two in vitro cell 
models previously established by us [34] (Figure 3). The 
two models are based on the PTC-driving oncogene RET/
PTC1 and include primary human thyrocytes exogenously 
expressing RET/PTC1 (Model 1; Figure 3A) and the PTC-
derived cell line TPC1, harboring endogenous RET/PTC1, 
treated with the RPI-1 inhibitor (Model 2; Figure 3B). 
The rationale for this analysis derived from the notion that 
in PTC different tumor-driving alterations converge on 
common signaling pathways (namely MAPK and PI3K/
AKT pathway) [7], and that the use of these two cell 
models has already been helpful in the identification of 
functionally relevant miRNAs in PTC [34].
When we compared the three signatures, we 
found four consistently and concordantly deregulated 
miRNAs, including the upregulated miR-222-3p and the 
downregulated miR-451a, miR-199a-3p and miR-214-3p 
(Figure 3C). Of note, all these miRNAs appear relevant 
as: (i) the overexpression of miR-222-3p has broadly been 
reported (Figure 2) and is considered a hallmark of thyroid 
malignancy; (ii) the downregulation of miR-199a-3p and 
miR-214-3p, both included in the cluster miR-199a-2/214, 
has already been showed by us [34]; and (iii) miR-451a 
has been identified by our meta-analysis as the most 
frequently reported downregulated miRNA (Figure 2). We 
next focused on miR-451a as its involvement in various 
malignancies has already been reported, but in the context 
of PTC its functional role has not been investigated before.
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Figure 1: miRNA expression profiles in PTC clinical samples A. Heat map showing miRNAs differentially expressed between 
PTC and normal thyroid tissues (absolute FC≥1.5; FDR<0.05). B-C. miRNA expression in the validation set of 499 PTC and 59 normal 
thyroid tissues derived from TCGA. miR abundance is reported as log2 normalized (reads-per-million, RPM) median-centered; q-value, 
statistical significance calculated by Wilcoxon test adjusted by Benjamini-Hochberg correction.
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miR-451a expression relative to clinical 
pathological features and genetic lesions
Starting from the notion that in various types of 
tumors low expression of miR-451a significantly correlates 
with aggressive clinical-pathological features, we tested 
whether a similar correlation existed also in PTC. As 
our PTC series was too small for appropriate samples 
stratification, we exploited once again the large cohort of 
PTC/normal thyroid samples of TCGA (Figure 4).
PTC samples were stratified based on the following 
clinical-pathological features: histological type (A), 
pathological TNM stage (B), extrathyroid extension (ETE) 
(C), tumor size (D), T stage (E) and N stage (lymph node 
metastases) (F); classification based on M stage was not 
applicable in the tested case list as only a few samples 
(8/499) presented distant metastases.
For all the tested parameters we observed that 
miR-451a expression was lower in each tumor subgroup 
than in normal thyroids (p-value <0.0001). Among 
PTCs, miR-451a expression was significantly lower in 
samples characterized by a more aggressive variant (tall 
cell; Figure 4A), advanced stage (stage III or IV; Figure 
4B) and presence of ETE (Figure 4C). By contrast, no 
significant differences were found based on tumor size, T 
and N stage (Figure 4D–4F).
Then, the expression of miR-451a was further 
investigated in relation to different genetic lesions (Figure 
4G). PTC samples were stratified based on various genetic 
lesions derived from the original study from TCGA [7] 
including: (i) mutations of BRAF, RAS and EIF1AX genes, 
(ii) fusions of RET, NTRK, PPARG, BRAF and “other 
genes” and (iii) group termed “Rest” comprising samples 
with other genetic lesions.
We found that the expression of miR-451a was 
significantly lower in each molecular subgroup of PTC 
than in normal thyroids (p-value <0.005), with the 
exception of EIF1AX mutated samples (p-value =0.27). 
Among PTCs we observed similar expression of miR-
451a and significant differences were observed only 
in samples with BRAFV600E and EIF1AX mutations 
(p-value <0.05), showing lower and higher levels of miR-
451a, respectively.
Table 1: Overview of the 15 studies selected from literature
Study









1 He (2005) [8] snap-frozen 15 15, paired microarray
2 Pallante (2006) [9] snap-frozen 30 10, paired microarray
3 Nikiforova (2008) [10] snap-frozen 9 5 qRT-PCR panel
4 Chen (2008) [11] FFPE 32 5 qRT-PCR
5 Sheu (2010) [12] FFPE 10 10, paired qRT-PCR
6 Chou (2010) [13] snap-frozen 100 16, paired qRT-PCR
7 Lassalle (2011) [14] snap-frozen 16 16, paired microarray
8 Yip (2011) [15] snap-frozen 12 4 microarray
9 Huang (2013) [16] snap-frozen 12 3, paired microarray
10 Zhang (2013) [17] snap-frozen 3 3, paired microarray
11 Wang (2013) [18] snap-frozen 6 2, paired microarray
12 Dettmer (2013) [19] FFPE 44 8 qRT-PCR panel
13 Swierniak_1 (2013) [20] snap-frozen 14 14, paired NGS
    Swierniak_2 (2013) [20] snap-frozen 14 14 NGS
    Swierniak_3 (2013) [20] snap-frozen 9 9, paired microarray
14 TCGA_1 (2014) [7] snap-frozen 59 59, paired NGS
    TCGA_2 (2014) [7] snap-frozen 499 59, paired NGS
15 Mancikova (2015) [21] snap-frozen 78 17 NGS
    Our study snap-frozen 19 5 microarray
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Figure 2: Meta-analysis of miRNA expression profiles in PTC versus normal thyroid. Study-miRNA matrix showing 
miRNA expression across the 15 studies selected from literature and our study. Color code: red, upregulated; green, downregulated. 
Score is calculated based on the reporting frequency of each miRNA. Matrix selectively represents only miRNAs reported in at least two 
independent studies (complete data available in Supplemental Table S3); the three and two datasets derived from study 13 (Swierniak 2013) 
and from study 14 (TCGA 2014), respectively, were considered as single studies.
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Overall these data, showing that miR-451a is 
significantly underexpressed in PTC and is differentially 
expressed according to specific clinical-pathological 
features and genetic lesions, prompted us to further 
investigate its functional role in the context of PTC.
miR-451a functional studies
Firstly, we evaluated the expression of miR-451a 
in a set of PTC-derived cell lines including TPC1, 
NIM1, K1 and BCPAP (Figure 5A). In agreement with 
data obtained in PTC specimens, we found that miR-
451a was markedly downregulated in all the tested cell 
lines compared with the control cells T686. As several 
experimentally validated targets of miR-451a have 
been identified [33] and among these MIF is the most 
consistently reported (miRTarBase ID MIRT000046), 
we assessed MIF basal expression in the same panel of 
cell lines (Figure 5B). We observed that MIF protein was 
expressed at higher level in three out of the four tested 
cell lines compared with the control cell T686. Analyzing 
MIF expression in relation to miR-451a (Figure 5C), 
we found a general pattern of anticorrelation (3/4 of 
the tested cell lines), according to the expected inverse 
relationship between a miRNA and its target gene. Based 
on this result, we selected for the subsequent analyses 
NIM1 and TPC1 cell lines that, harboring BRAFV600E 
mutation and RET/PTC1 rearrangement, respectively [35, 
36], are representative of the mutation and gene fusion 
most frequently identified in PTC.
The functional role of miR-451a was investigated 
in both cell lines by the transfection of a miR-451a 
synthetic miRNA mimic. We verified in both cell lines 
that following transfection, miR-451a was efficiently 
overexpressed and concomitantly MIF protein level 
was strongly decreased (Supplementary Figure 
S4A). In functional assays we found that the ectopic 
expression of miR-451a significantly impaired cell 
growth, assessed by cell number count (Figure 5D and 
5G) and proliferation assay (Figure 5E and 5H), and 
moderately reduced migratory ability (Supplementary 
Figure S4B-C).
To better understand the biological effects induced 
by miR-451a, we performed biochemical analyses (Figure 
5F and 5I). In both cell lines we found that the ectopic 
expression of miR-451a was associated not only with the 
expected reduction of the validated targets MIF, c-MYC 
and AKT but also with decreased phosphorylation of AKT 
Figure 3: Combined analysis of miRNAs in PTC clinical samples and in vitro cell models A-B. Schematic representation 
of the two complementary in vitro cell models based on the PTC-driving oncogene RET/PTC1. Model 1: human primary thyrocytes 
exogenously expressing RET/PTC1; Model 2: PTC-derived cell line TPC1 expressing endogenous RET/PTC1 treated with the RET 
inhibitor RPI-1. C. Venn diagram of miRNAs differentially expressed in clinical specimens (PTC vs. normal thyroid, absolute FC ≥1.5; 
FDR<0.05; see Supplemental Table S2) and in cell models (Model 1: RET/PTC1-expressing thyrocytes vs. parental thyrocytes, absolute 
FC ≥2.5; Model 2: TPC1 treated with solvent DMSO vs. TPC1 treated with RPI-1, absolute FC ≥2.5 and FDR <0.1). Common miRNAs 
concordantly expressed in the 3 datasets are indicated in the right boxes.
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Figure 4: miR-451a expression relative to clinical pathological features and genetic lesions. miR-451a expression in the 
set of 59 normal thyroid (NT) and 499 PTC samples derived from TCGA and stratified according to A. histological type (Fv, Follicular 
variant; Cv, Classic variant; TCv, Tall Cell variant), B. pathological TNM stage, C. extrathyroid extension, ETE (None, absence of ETE; 
Min, Minimal; Mod/Adv, Moderate/Advanced), D. tumor size, E. T stage, F. N stage (N0, absence of lymph node metastases; N1 presence 
of lymph node metastases) and G. genetic lesion (mut, mutation; fus, fusion; Rest, samples harboring other genetic lesions). miR-451a 
abundance is reported as log2 normalized (reads-per-million, RPM) and represented by box plots. In parentheses the number of samples 
included in each group. P, statistical significance by Kruskal-Wallis test. * p-value<0.05, ** p-value<0.01 by Wilcoxon test.
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Figure 5: miR-451a functional studies A. miRNA-451a expression by qRT-PCR in the PTC-derived cell lines TPC1, NIM1, K1 and 
BCPAP, and in the normal thyroid control cells T686. Data are presented relative to the value of T686 cells. B. MIF protein expression 
by western blot analysis (WB) in the same panel of cell lines; Actin is shown as loading control. Below the corresponding densitometric 
quantification; MIF expression was normalized to Actin and presented relative to the level of T686 cells. C. Relative expression of the 
pair miR-451a and MIF; data are derived from the analyses reported in (A) and (B). D-I. Functional studies in NIM1 and TPC1 cells 
either transfected with miR-451a synthetic mimic (miR-451a) or Negative-Control (NC). D, G. Representative images of transfected 
cells (LEICA inverted microscope, scale bar 100μm). Cell number was determined by nuclei staining; data are presented relative to NC-
transfected cells. E, H. Cell proliferation following transfection. F, I. WB analysis (day 3 after transfection). Protein expression was 
quantified and normalized to the loading control GAPDH. Data are presented relative to NC-transfected cells. Graphs report mean ± s.e.m. 
of at least two independent experiments. * p-value<0.05, ** p-value<0.005, *** p-value<0.0001 by Student’s t-test.
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downstream effectors such as mTOR and S6 proteins. In 
detail, marked reduction was observed for MIF (mean 
reduction of 96% and 71% in NIM and TPC1 cells, 
respectively), AKT (mean reduction of 71% and 54%) 
and c-MYC (mean reduction of 24% and 62%) proteins. 
In addition, reduced levels of the phosphorylated proteins 
AKT (mean reduction of 26% and 15%), mTOR (mean 
reduction of 31% and 45%) and S6 (mean reduction of 
33% and 41%) were detected. A clear reduction of total 
S6 protein (mean reduction of 44% and 42%) was also 
observed.
Collectively, these results suggest that in PTC-
derived cell lines miR-451a displays tumor suppressor 
functions and targets multiple elements of the AKT/mTOR 
pathway.
DISCUSSION
In this study we identified a panel of deregulated 
miRNAs in PTC specimens compared to normal 
thyroid and among these we showed that miR-451a is 
underexpressed and displays tumor suppressor functions 
by targeting multiple elements of the AKT/mTOR 
pathway. Our experimental strategy included: miRNA 
profiling, validation in an independent dataset from 
TCGA, literature review and meta-analysis, combined 
analysis of PTC clinical samples and in vitro cell models 
and functional studies.
Firstly, by miRNA profiling we identified a panel of 
18 miRNAs significantly deregulated in PTC compared 
to normal thyroid. This miRNA signature was able 
both to separate tumor samples from normal thyroid 
and to partially sub-stratify PTC samples according to 
histological variants. The most significant separation was 
observed for the follicular variant that form an individual 
cluster separate from the other PTCs. This is consistent 
with previous reports [7, 19, 21] that highlighted how 
follicular variant PTCs represent a peculiar entity among 
PTCs sharing features with both PTC and follicular thyroid 
carcinoma (FTC). In addition, we identified two further 
clusters enriched for the classical (cluster 3) and for the tall 
cell variant (cluster 4), even though more heterogeneity, 
especially in the tall cell-enriched group (cluster 4), was 
found. However, due to intrinsic heterogeneity and to 
possible co-presence of different histological patterns in 
the same tumor, a complete separation among distinct 
histotypes may not occur as already reported [10], also in 
larger PTC cohorts [7, 19, 21].
As in the last decade several studies had already 
investigated miRNA expression in PTC, we compared our 
miRNA signature with those published. We performed a 
literature review; for a more homogeneous comparison, 
we applied stringent criteria of selection and we 
specifically focused only on studies using normal thyroid 
samples as healthy control group. However, a direct 
studies comparison resulted difficult, mostly because 
in some instances was applied heterogeneous miRNA 
nomenclature specific of different releases of miRBase. 
To overcome this problem, the identity of each miRNA 
was checked and updated according to miRBase (v21) 
mature sequence accession (i.e. MIMAT accession); 
this univocal ID was then used for a direct studies 
comparison. To our knowledge, this is the first report, 
among those analyzing miRNA profiles in PTC, that 
exploited this approach. Furthermore, for the first time, 
we included in our review the more recent publications 
in which miRNA expression was investigated by NGS 
[7, 20, 21].
Our meta-analysis not only underlined a set of 
upregulated miRNAs common to most studies [23, 
24], but also identified a set of downregulated miRNAs 
consistently reported in the most recent studies. Recently, 
Riesco-Eizaguirre et al. determined by NGS miRNA 
deregulation in 8 matched PTC/normal thyroid samples 
[37]; their data are very consistent with those reported 
by our meta-analysis, providing further support to our 
results. Interestingly, some of the top downregulated 
miRNAs here identified, as miR-451a and miR-486-5p, 
had already been reported as unpublished data [38, 39]. 
Thus, our meta-analysis not only confirmed literature data 
but also shed new light on specific deregulated miRNAs 
whose possible relevance in PTC has been previously 
underestimated.
Along with the most frequently reported deregulated 
miRNAs, we identified several miRNAs reported only 
by a fraction of the analyzed studies. However, these 
miRNAs result of interest as they belong to specific 
miRNA families/clusters/precursors and thus appear 
in some way “linked” to each other. Indeed, miRNAs 
included in a gene family display sequence similarity, 
especially in the seed region, while miRNAs included 
in a cluster or precursor display physical proximity as 
they are transcribed in a single polycistronic transcript or 
derive from the same hairpin pre-miRNA, respectively. 
Collectively, these high related miRNAs are thought to 
be functionally related and to cooperate in the regulation 
of multiple biological processes either by co-targeting 
the same gene or different components of the same 
pathway. Interestingly, consistent patterns of deregulation 
have already been found in various tumors for these 
high related miRNAs [40]. Thus, the identification of 
concordant deregulation of miRNA families (e.g. miR-
221,-146, -181, -199) or clusters (e.g. miR-221/222, 
-181a/181b, -451a/144, -7-2/1179) or mature miRNAs 
originated from the same precursor (e.g. miR-221-3p/5p, 
-146b-5p/3p, -21-5p/3p, -144-5p/3p, -199a-5p/3p, -486-
5p/3p) in both up and downregulated miRNAs, suggests 
a major consistency for the their biological relevance in 
the pathology of PTC and provides a strong rationale to 
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further investigate their role in this neoplasia by future 
studies.
The miRNA signature here identified, although 
derived from a small series of clinical samples, not only 
has been validated in an independent and larger cohort 
derived from TCGA, but also resulted consistent with 
literature data both in the general miRNA profile and in 
the coordinated deregulation of miRNA families/clusters/
precursors.
Our meta-analysis identified miR-451a as the most 
frequently reported downregulated miRNA (Figure 2). In 
addition, miR-451a emerged also in the set of relevant 
miRNAs identified both in PTC clinical samples and in 
vitro cell models (Figure 3). These findings suggested the 
possible involvement of miR-451a in PTC and prompted 
us to focus on this miRNA.
In line with data reported in other tumors, we found 
a significant association between low expression of miR-
451a and aggressive clinical-pathological features of PTC 
as tall cell variant, advanced TNM stage and presence of 
ETE, but not with tumor size, T and N stage. Recently, 
a systematic review [41] reported in PTC an association 
of miR-451a with lymph node metastases (LNM or also 
defined as N stage) and this may appear in contrast with 
our study. However, the association described by Aragon 
Han et al [41] was derived from a single study [42] and 
some considerations should be made about that study: first, 
miR-451a was reported moderately higher in patients with 
LNM (FC 1.6, P value 0.026) and this appear in contrast 
with data reported in other tumors [29, 32]; second the 
tested case list was smaller than that analyzed in the 
present study (87 and 446 PTC samples, respectively).
Among various genetic lesions we found 
significantly lower level of miR-451a in PTC patients with 
BRAFV600E mutation. Because in PTC this mutation has 
already been associated with poor clinical-pathological 
parameters [16, 19], this finding confirms the above 
mentioned association of miR-451a with aggressive 
features of PTC. Notably, a significant difference is also 
observed in PTCs with EIF1AX mutations in which miR-
451a levels result higher if compared to the other PTC 
molecular subgroups.
EIF1AX encodes the translation initiation factor 
eIF1A that recently has been reported to promote the 
biogenesis of miR-451a by interacting with Ago2 
protein [43]. The expression and the activity of eIF1A 
thus appear to be directly linked to mature miR-451a 
levels. In line with this notion, we found that EIF1AX 
is moderately but significantly underexpressed in PTC 
samples derived from TCGA (Supplemental Figure S5A); 
we could speculate that reduced expression of EIF1AX 
might cooperate or might be in part responsible of miR-
451a downregulation in PTC. Our observation that PTCs 
with EIF1AX mutations express more miR-451a than 
PTCs with other genetic lesions (Figure 4G) is intriguing, 
although its significance remain to be determined. One 
hypothesis could be that these mutations might alter the 
eIF1A protein function and/or interaction with Ago2 and 
might promote a more effective processing and maturation 
of miR-451a. However, the functional effect of EIF1AX 
mutations is still unknown and further studies are required 
to test this hypothesis. As EIF1AX mutations have been 
recently found in various tumors [44–46], including 
thyroid tumors other than PTC [47], the identification of 
additional elements (e.g. miR-451a) linked to this gene is 
of general interest. However, as some EIF1AX mutations 
have been suggested to cause loss or impairment of protein 
function rather than gain [44, 46], we cannot exclude the 
possibility that additional mechanisms, not directly related 
to EIF1AX mutation, could contribute to the miR-451a 
higher expression in PTC patients with EIF1AX mutations.
The key role of miR-451a has already been 
demonstrated in various types of cancers. To our 
knowledge, its role in PTC has not been investigated 
before. Thus, to elucidate the processes and pathways 
regulated by miR-451a, we performed functional studies 
in PTC-derived cell lines. In agreement with previous 
reports [26–28, 31, 32], we found that the ectopic 
expression of miR-451a impairs cell proliferation and 
migration. Along with these biological effects, we 
observed the reduction at protein level of its validated 
targets MIF, c-MYC and AKT.
MIF is a pro-inflammatory cytokine overexpressed 
in various tumors, where it promotes tumor growth 
and progression by the activation of multiple signaling 
cascades, including AKT pathway [48]. Recently, its 
involvement has been described also in PTC. In detail, 
two independent studies showed that the pharmacological 
inhibition either of MIF [49] or its receptor CD74 [49, 
50] impairs proliferation and migration of PTC-derived 
cell lines and reduces the activation of AKT/mTOR 
pathway. In line with these findings, here we showed that 
the inhibition of MIF protein expression by miR-451a, 
along with other target genes, impairs proliferation and 
migration. Interestingly, both studies [49, 50] described 
in PTC specimens a consistent overexpression of the MIF 
receptor and a trend toward MIF protein overexpression. 
According with these studies, we observed a moderate but 
significant overexpression of MIF in PTC samples derived 
from TCGA (Supplemental Figure S5B). Together these 
findings provide additional support for a role of MIF and 
its associated regulatory and signaling pathways, including 
miR-451a, in the context of PTC.
c-MYC is a well known transcription factor that 
integrating signals from multiple pathways, including 
AKT pathway, controls gene expression and cellular 
functions as cell proliferation, differentiation and 
transformation [51]. Importantly, c-MYC is an established 
oncogene and its aberrant activation occurs in many 
human cancers [51]. c-MYC deregulation has been found 
also in PTC where it is overexpressed at protein [52, 53] 
but not at mRNA level [52, 54, 55]. According to this, in 
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PTC samples from TCGA we did not find c-MYC mRNA 
overexpression (Supplemental Figure S5C); by contrast, 
we found its moderate but significant underexpression. 
This finding, although unexpected, is in agreement with 
previous reports [52, 55] showing that c-MYC transcript 
level was lower in some thyroid tumors than in their 
normal counterpart. However, the significance of this 
finding remains to be elucidated.
As it is broadly recognized that miRNAs can 
regulate target genes by translation blockage without 
changes of mRNA level, we could hypothesize that in PTC 
miR-451a may regulate c-MYC by a similar mechanism. 
Interestingly, Kim et al. have recently proposed that in 
PTC c-MYC overexpression could be due to c-MYC 
protein stabilization induced by activated AKT signaling 
[52]. These findings thus suggest that in PTC c-MYC 
overexpression may occur by multiple mechanisms, 
including regulation by miRNAs (e.g. miR-451a) and 
post-translational events, that do not necessary involve 
mRNA level changes.
Here we showed that miR-451a mimic reduces 
both the c-MYC protein levels and the activation of 
AKT pathway (Figure 5F and 5I). As activated AKT 
pathway directly controls c-MYC protein levels [52], 
we cannot exclude the possibility that the observed 
reduction of c-MYC protein may be due to the combined 
action of miR-451a not only on c-MYC but also on its 
upstream regulators, namely on AKT. Indeed, AKT 
(specifically AKT1) is a target of miR-451a (miRTarBase 
ID MIRT005740) and consistently with this notion, we 
showed its reduction following miR-451a transfection.
AKT is a central mediator in the PI3K/AKT/mTOR 
pathway that in turn regulates fundamental cellular 
processes as proliferation and migration. Importantly, AKT 
is activated in many cancers, including thyroid carcinomas, 
where it is involved in tumor formation and progression 
[56]. Evidence of its activation has been reported also in 
PTC [7] and a trend toward AKT1 overexpression, both 
at mRNA and protein level, has already been described 
[57]. In line with these observations, we found a moderate 
but significant overexpression of AKT1 mRNA in PTC 
samples from TCGA (Supplemental Figure S5D).
In biochemical analyses, consistently with AKT 
reduction, we observed decreased phosphorylation of its 
downstream effectors mTOR and ribosomal protein S6, 
indicative of reduced pathway activation. Interestingly, 
we found also decreased expression of total S6 protein. 
However, this reduction may be due to feedback 
regulation rather than to a direct targeting by miR-451a. 
Indeed, S6 is not a reported target of miR-451a (according 
to miRTarBase v16) and we have previously showed 
its decrease following mTOR silencing [34]. Thus, we 
hypothesize that miR-451a by targeting AKT indirectly 
impairs the downstream activation of mTOR and this in 
turn causes S6 protein reduction.
Collectively, our functional analyses showed that 
in PTC, miR-451a affects cell proliferation and migration 
and targets multiple elements of the AKT/mTOR pathway, 
thus appearing to play a role as tumor suppressor miRNA 
in this neoplasia. We are aware that here we focused 
primarily on selected targets of miR-451a, already 
validated in other experimental sets, and that the identified 
link miR-451a/AKT pathway may represent only one, 
among many, of the molecular mechanisms by which this 
miRNA exerts its functions. Additional and more in-depth 
studies are thus required to fully elucidate the biological 
role of miR-451a in PTC. However, to our knowledge this 
is the first study investigating the functional role of miR-
451a in PTC and the identification of a link miR-451a/
AKT pathway in this tumor is noteworthy. Indeed, AKT 
pathway, along with MAPKs pathway, is a central hub in 
the signaling networks involved in thyroid carcinogenesis 
and several deregulated miRNAs have already been 
reported to target this pathway at multiple levels (reviewed 
in [23, 39]). Thus, the identification of miR-451a as an 
additional regulator of AKT pathway provides further 
evidence of the complexity of the molecular mechanisms 
involved in the control of this pathway crucial for both 
normal and neoplastic thyroid.
In summary, in this is work we gave a 
comprehensive and updated overview of the current 
knowledge about miRNA deregulation in PTC showing 
that along with the well known upregulated miRNAs a 
set of miRNAs emerges as consistently downregulated. 
In addition, we provided the first functional evidence 




Nineteen PTC and five normal thyroid samples were 
obtained from the Department of Pathology, Fondazione 
IRCCS Istituto Nazionale dei Tumori (INT), Milan, 
Italy. PTC samples were classified according to WHO 
Classification [58] and to pathological tumor-node-
metastasis (pTNM) staging system [59] by an expert 
pathologist; normal thyroid samples were obtained from 
patients with pathologies other than thyroid cancer. 
Informed consent was obtained by all patients whose 
biological samples were used in the study and the 
experimental protocol was approved by the Independent 
Ethical Committee of INT. Tumor samples were screened 
for the most common mutations and rearrangements 
reported in PTC including BRAF (exon 15), NRAS (exon 
2) and HRAS (exon 2) mutations and RET and NTRK1 
rearrangements. Detailed methods are described in 
Supplemental Materials and Methods.
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miRNA microarray analysis
Total RNA was extracted from snap-frozen 
tissues using the miRNeasy Mini kit (Qiagen). RNA 
concentration was measured with the NanoDrop ND-100 
Spectrophotometer (NanoDrop Technologies, Wilmington, 
DE) and RNA quality was assessed with the Agilent 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNA 
was labeled and processed according to the manufacturer’s 
recommended protocol and miRNA expression analysis 
was assessed using SurePrint G3 Human miRNA 8x60K 
microarrays from Agilent Technologies. Briefly, 100ng of 
RNA were dephosphorylated with calf intestinal alkaline 
phosphatase and denatured in the presence of DMSO. 
Samples were fluorescently labeled with cyanine 3-pCp 
using T4 RNA ligase and hybridized on miRNA array. 
Arrays were washed in Agilent GE Wash Buffers and 
scanned at resolution of 2 mm using an Agilent DNA 
microarray scanner.
Data were acquired using Agilent’s Feature 
Extraction software v10.7 and were analyzed using R 
programming language [60] and related Bioconductor 
[61] packages. Raw miRNA expression data were 
preprocessed using an optimized version of the RMA 
algorithm implemented in the AgiMicroRna package [62] 
and miRNAs detected in at least 15 samples (according 
to the gIsGeneDetected information given by the Feature 
Extraction software) were selected for further analyses. 
miRNAs differentially expressed between PTC and 
normal thyroid were identified using the limma package 
[63]. Multiple-testing correction was performed using the 
Benjamini-Hochberg false discovery rate (FDR) [64] and 
miRNAs with FDR < 0.05 and absolute fold-change ≥ 
1.5 were considered significant. Clusters enrichment was 
determined by one-sided Fisher’s exact test comparing 
each cluster with the others. Microarray data were 
deposited and are available on NCBI Gene Expression 
Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo/) 
with the accession number GSE73182.
TCGA data analysis
miRNA datasets were retrieved from Illumina 
HiSeq Level 3 isoform quantification files [7] archived 
at the TCGA Data Portal website (http://tcga.cancer.gov/
dataportal; accessed May 2015). The normalized reads 
per million miRNA mapped (RPM) data were obtained 
in 499 PTC and 59 normal thyroid samples by summing 
up the read counts at mature and star strand resolution for 
each MIMAT accession (miRBase v16), as described [65]. 
Mature miRNA species were then reannotated according 
to miRBase v21 (http://www.mirbase.org/) [66].
RPM data of the 18 miRNAs identified in this study 
were extracted both for 499 PTCs and 59 normal thyroids 
and for 59 matched PTC/normal thyroid cases. Data 
were log2 transformed after replacing the values equal 
to zero with the minimum non-null value. Differential 
miRNA expression between two groups was evaluated 
using Wilcoxon test. Adjustment for multiple testing 
was performed by Benjamini-Hochberg correction. 
Hierarchical clustering of the 59 matched PTC/normal 
thyroid samples was performed in DNAChip software [67] 
using pearson correlation and average as distance metric 
and linkage method, respectively, based on the expression 
profiles of our miRNA signature.
Differential expression of miR-451a in normal 
thyroid and PTC samples, stratified in multiple groups 
according to clinical-pathological features and genetic 
lesions [7], was evaluated using Kruskal Wallis test.
Literature review and meta-analysis
A primary literature search was performed in 
PubMed (www.ncbi.nlm.nih.gov/pubmed) using the 
terms ‘thyroid cancer’ and ‘miRNA’ and all conceivable 
synonyms with limitations in ‘human’ and ‘English’ for 
paper published prior to July 31, 2015. Publications were 
considered eligible if they met the following criteria: (1) 
studies examining miRNAs in PTC, (2) studies examining 
miRNAs in thyroid cancers including PTC, (3) normal 
thyroid paired/unpaired used as healthy control group 
(4) miRNAs derived from tissue samples. Studies were 
excluded based on the following criteria: (1) reviews, 
single case reports, meta-analyses and abstract presented 
in conferences (2) absence of healthy control groups or 
use of healthy control groups other than normal thyroid as 
multinodular goiter, follicular adenomas or benign lesions 
(3) intra-tumoral comparisons as benign vs. malignant 
thyroid lesions or PTC not aggressive vs. aggressive 
(4) less than 3 miRNAs tested (5) circulating miRNAs 
assessment. According to our inclusion criteria, 15 studies 
were selected and full-text publications were reviewed in 
their entirety.
For meta-analysis and studies comparison, miRNA 
data were retrieved from the original publications and 
updated according to the most recent release of miRBase. 
In detail, the identity of each miRNA was verified by 
miRBase (v21) [66] and/or miRBase Tracker (www.
mirbasetracker.org/index.php) [68] and an updated ID 
corresponding to MIMAT accession (miRBase v21) 
was assigned. A study-miRNA matrix was constructed 
using miRNA signature derived from each study and 
MIMAT accessions. Specific criteria of data filtering and 
cutoffs were applied for each study and are described in 
Supplemental Materials and Methods.
In vitro models and cell cultures
The two in vitro cell models exploited in this 
study are based on RET/PTC1 oncogene and were 
previously described [34]. The miRNA expression 
profiles derived from both models were deposited 
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on GEO database (superSeries GSE49415) and have 
already been reported [34].
The cell lines TPC1, NIM1, K1 and BCPAP 
are derived from human PTC and have already been 
characterized for driving genetic lesions [35, 36]. The 
control cells T686 are derived from immortalized primary 
human non-neoplastic thyrocytes. Cell lines were cultured 
either in DMEM (TPC1, NIM1, and BCPAP) or DMEM: 
Ham’s F12: MCDB at the ratio of 2:1:1 (K1 and T686) 
(Gibco, Thermo Fisher Scientific). All culture media were 
supplemented with 10% fetal bovine serum (EuroClone), 
and cells were maintained at 37°C and 5% CO2. Cell lines 
were authenticated by short tandem repeat (STR) profiles 
using the StemElite ID System (Promega) by the Fragment 
Analysis Facility at INT. Cells were routinely tested for 
mycoplasma.
miR-451a expression in cultured cell lines
The endogenous expression of miR-451a in TPC1, 
NIM1, K1, BCPAP and T686 cell lines was determined by 
two-step quantitative real-time PCR. Total RNA, including 
miRNA fraction, was extracted from cultured cells with 
miRNeasy mini kit (Qiagen) and reverse-transcribed with 
TaqMan MicroRNA Reverse Transcription Kit (Applied 
Biosystems, Thermo Fisher Scientific). cDNA was 
amplified using TaqMan MicroRNA Assays together with 
TaqMan Universal PCR Master Mix (Applied Biosystems) 
on ABI PRISM 7900HT Real-Time PCR system. Data 
were analyzed with SDS 2.4 and RQ Manager 1.2.1 
software (Applied Biosystems) using the 2−ΔΔCt method. 
U6-snRNA was used as endogenous control for RNA input 
normalization.
Transfection and functional studies
The ectopic expression of miR-451a was obtained 
in NIM1 and TPC1 cells by the transfection of miR-
451a synthetic miRNA mimic (PM10286 Applied 
Biosystems) at 100 nM by siIMPORTER Transfection 
Reagent (Millipore, Billerica, MA); FAM-labeled 
Negative Control#1 (AM17121 Applied Biosystems) 
was transfected as negative control. Following 
transfection both cell lines were evaluated for cell 
number and proliferation. Cell number was assessed by 
NucleoCounter system (ChemoMetec A/S, Denmark) 
as previously described [34]. Cell proliferation was 
assessed by crystal violet assay. Briefly, at the indicated 
time points transfected cells were first fixed with 10% 
formalin for 20 min and then stained with 0.1% crystal 
violet (Sigma-Aldrich, MO, USA) for 30 min. After stain 
removal and PBS washes, the dye was solubilized with 
1% SDS and the absorbance was measured at 570nm 
by a microplate reader (TecanUltra, Tecan Trading AG, 
Switzerland).
Western blot analysis and antibodies
Total protein extraction, SDS PAGE and Western 
blot analyses were performed as previously described [69]. 
The primary antibody c-MYC (#5605), pAkt (Ser473, 
#4060), mTOR (#2983), pmTOR (Ser2448, #5536), 
S6 (#2217) and pS6 (Ser235/236, #4858) are from Cell 
Signaling Technology (Cell Signaling Technology Inc., 
MA, USA); MIF (ab175189) from Abcam (Abcam Inc., 
Cambridge, UK); AKT specific for AKT1 (#610861) 
from BD Transduction Laboratories (BD Biosciences, NJ, 
USA); Actin (A2066) from Sigma-Aldrich and GAPDH 
(#sc-32233) from Santa Cruz Biotechnology (Santa Cruz 
Biotechnology Inc., CA, USA). Relative protein levels 
were quantified by Quantity One 4.6.6 software (Bio-Rad, 
Hercules, CA).
Statistical analysis
Detailed statistical analyses are reported in the 
specific sections miRNA microarray and TCGA data 
analysis. For functional studies, statistical analyses and 
graphs were generated using GraphPad Prism version 
5.02; comparisons between two groups were performed by 
two-tailed Student’s t-test with unequal variance. p-value 
< 0.05 was considered statistically significant.
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